Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 5/20 | 0.50 |
| ▸ | HTR6 | P50406 | 5/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 3/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13293836 | 0.94 | BAZ2B (0.46) | HDAC6HDAC1MAOAMAOBHRH1 | |
| SCHEMBL12820328 | 0.93 | HDAC6 (0.45) | HDAC6HDAC1MAOAMAOBHRH1 | |
| SCHEMBL168662 | 0.93 | HDAC1 (0.58) | HDAC6HDAC1HRH1HTR6BAZ2B | |
| SCHEMBL10315933 | 0.91 | HDAC6 (0.51) | HDAC6HDAC1MAOAMAOBHRH1 | |
| SCHEMBL169190 | 0.91 | HDAC6 (0.53) | HDAC6HDAC1MAOAMAOBHRH1 | |
| SCHEMBL12933210 | 0.90 | HDAC6 (0.55) | HDAC6HDAC1HRH1HTR6BAZ2B | |
| SCHEMBL167241 | 0.90 | HDAC6 (0.50) | HDAC6HDAC1MAOAMAOBHRH1 | |
| SCHEMBL13293842 | 0.86 | BAZ2B (0.50) | HDAC6HDAC1BAZ2BAKR1B10AKR1B1 | |
| SCHEMBL12820330 | 0.85 | HDAC1 (0.48) | HDAC6HDAC1BAZ2BAKR1B10AKR1B1 | |
| SCHEMBL13306462 | 0.84 | HDAC6 (0.44) | HDAC6HDAC1MAOAMAOBHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424366-B1 | PYRIDO [4, 3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2016-02-17 | — | — | EP | claimed |
| US-8927571-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-01-06 | — | — | US | claimed |
| US-8741919-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-03 | — | — | US | claimed |
| US-20130190331-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | claimed |
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-07-05 | — | — | US | claimed |
| CN-102480956-A | Pyrido [4,3-b] indoles and methods of use | MEDIVATION TECHNOLOGIES INC | 2012-05-30 | — | — | CN | claimed |
| EP-2424366-A1 | PYRIDO [4, 3-B]INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2011019417-A1 | PYRIDO [4, 3-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-02-17 | — | — | WO | claimed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2424366-B1 | PYRIDO [4, 3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2424366-B1 | PYRIDO [4, 3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| WO-2012154261-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | HDAC6 3393/4885HDAC1 4018/4885MAOA 75/4885 |
| US-20130190331-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | HDAC6 3393/4885HDAC1 4018/4885MAOA 75/4885 |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | HDAC6 2844/4885HDAC1 1375/4885MAOA 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.